Please assess the completion status of the following clinical trial:

Trial Title: GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with cytologically or histologically proved biliary tract cancer~2. age \>=20 years~3. Performance Status (PS) 0-2~4. No prior history of chemotherapy or radiotherapy.~5. Adequate bone marrow function (neutrophil count \>=1,500/mm3, and platelet count \>=100,000/mm3), liver function (total bilirubin \>=3 mg/dL and AST/ALT \>=150 IU/L), and renal function (creatinine clearance \>=45 mL/min)~6. Adequate oral intake~7. Provided written informed consent -~Exclusion Criteria:~1. Patients with interstitial pneumonia or pulmonary fibrosis~2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months~3. Patients with severe active infection~4. Patients with moderate or marked pleural effusion or ascites necessitating drainage~5. Patients with a history of severe drug allergy~6. Patients with other serious comorbid disease~7. Patients who are pregnant or lactating, or have an intention to get pregnant~8. Patients with mental disease~9. Patients who are judged inappropriate for the entry into the study by the principle doctor~   -

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine/Cisplatin group (Type: EXPERIMENTAL): Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
- Gemcitabine/Cisplatin /S-1 group (Type: EXPERIMENTAL): S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).